Increased plasma DPP4 activities predict new-onset atherosclerosis in association with its proinflammatory effects in Chinese over a four year period: A prospective study

Atherosclerosis

Volumn 235, Issue 2, 2014, Pages 619-624

  Zheng, T P ^a   Yang, F ^a   Gao, Y ^b   Baskota, A ^b   Chen, T ^b   Tian, H M ^b   Ran, X W ^b  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Atherosclerosis; C IMT; DPP4 activity; Inflammation

Indexed keywords

C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; TRIACYLGLYCEROL; DPP4 PROTEIN, HUMAN;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD SAMPLING; BODY MASS; CAROTID ATHEROSCLEROSIS; CHINESE; CHOLESTEROL BLOOD LEVEL; COMMON CAROTID ARTERY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIET RESTRICTION; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; INFLAMMATION; INSULIN BLOOD LEVEL; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MIDDLE AGED; MULTIPLE LINEAR REGRESSION ANALYSIS; PLASMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SAMPLE SIZE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO; ASIAN CONTINENTAL ANCESTRY GROUP; ATHEROSCLEROSIS; BLOOD; CHEMICALLY INDUCED; CHINA; ECHOGRAPHY; PATHOLOGY;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; ATHEROSCLEROSIS; CAROTID ARTERY, COMMON; CAROTID INTIMA-MEDIA THICKNESS; CHINA; DIPEPTIDYL PEPTIDASE 4; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFLAMMATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84908234371     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.05.956     Document Type: Article

References (19)

1. Hansson G.K., Robertson A.-K.L., Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol Mech Dis 2006, 1:297-329.
2. Hartman J., Frishman W. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol. Rev. 2014, 22:147-151.
3. Matteucci E., Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem 2009, 16:2943-2951.
4. Lamers D., Famulla S., Wronkowitz N., Hartwig S., Lehr S., Ouwens D.M., et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011, 60:1917-1925.
5. Itou M., Kawaguchi T., Taniguchi E., Sata M. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol 2013, 19:2298.
6. Zhong J., Rao X., Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 2013, 226:305-314.
7. Cordero O.J., Salgado F.J., Viñuela J.E., Nogueira M. Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes. Immunobiol 1997, 197:522-533.
8. Ikushima H., Munakata Y., Iwata S., Ohnuma K., Kobayashi S., Dang N.H., et al. Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cell Immunol 2002, 215:106-110.
9. Matsubara J., Sugiyama S., Sugamura K., Nakamura T., Fujiwara Y., Akiyama E., et al. Adipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. JAm Coll Cardiol 2012, 59:265-276.
10. Yang W., Lu J., Weng J., Jia W., Ji L., Xiao J., et al. Prevalence of diabetes among men and women in China. NEngl J Med 2010, 362:1090-1101.
11. Hodis H.N., Mack W.J., LaBree L., Selzer R.H., Liu C.-r., Liu C.-h., et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998, 128:262-269.
12. de Groot E., Hovingh G.K., Wiegman A., Duriez P., Smit A.J., Fruchart J.-C., et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004, 109:III-33-III-38.
13. Rose G.A., Blackburn H. Cardiovascular survey methods. Monograph series World Health Organization 1968, 56:1-188.
14. Touboul P.-J., Hennerici M., Meairs S., Adams H., Amarenco P., Desvarieux M., et al. Mannheim intima-media thickness consensus. Cerebrovasc Dis 2004, 18:346-349.
15. Yang F., Zheng T., Gao Y., Baskota A., Chen T., Ran X., et al. Increased plasma DPP4 activity is an independent predictor of the onset of metabolic syndrome in chinese over 4 years: result from the China national diabetes and metabolic disorders study. PloS One 2014, 9:e92222.
16. Nelson K.M., Boyko E.J., Koepsell T. All-cause mortality risk among a national sample of individuals with diabetes. Diabetes Care 2010, 33:2360-2364.
17. Kirino Y., Sei M., Kawazoe K., Minakuchi K., Sato Y. Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people. Endocr Journal 2011, 59:949-953.
18. Jeyaratnaganthan N., Højlund K., Kroustrup J.P., Larsen J.F., Bjerre M., Levin K., et al. Circulating levels of insulin-like growth factor-II/mannose-6-phosphate receptor in obesity and type 2 diabetes. Growth Horm IGF Res 2010, 20:185-191.
19. Shah Z., Kampfrath T., Deiuliis J.A., Zhong J., Pineda C., Ying Z., et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011, 124:2338-2349.